Wilson S G, Retallack R W, Kent J C, Worth G K, Gutteridge D H
Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia.
Clin Endocrinol (Oxf). 1990 May;32(5):613-22. doi: 10.1111/j.1365-2265.1990.tb00905.x.
The changes in three different indices of 1,25-dihydroxyvitamin D (1,25(OH)2D) biological activity were studied longitudinally in 35 women during late pregnancy and lactation and in 26 control women. Measurements were made of maternal serum total 1,25(OH)2D and free 1,25(OH)2D concentration (by centrifugal ultrafiltration) and the free 1,25(OH)2D index (the molar ratio of total 1,25(OH)2D and vitamin D binding protein (DBP]. During late pregnancy total 1,25(OH)2D concentrations were significantly elevated when compared to controls, as were free 1,25(OH)2D and DBP concentrations and the free 1,25(OH)2D index. Serum total 1,25(OH)2D, free 1,25(OH)2D and DBP concentrations all fell dramatically during the first 2 weeks of lactation with total 1,25(OH)2D and free 1,25(OH)2D concentrations falling to levels below those of controls. During the course of lactation both total 1,25(OH)2D and free 1,25(OH)2D levels rose significantly although they were not different from controls at 18 weeks of lactation. In contrast, the free 1,25(OH)2D index fell during the first 2 weeks of lactation, but remained at this level, significantly lower than controls. Neither urinary calcium excretion nor dietary calcium intake correlated with total or free 1,25(OH)2D, DBP, or the free 1,25(OH)2D index. The disagreement in the results of free 1,25(OH)2D concentration and free 1,25(OH)2D index demonstrates that these two approaches to measuring biologically active 1,25(OH)2D are not equivalent. In attempting to account for the increased calcium requirements of human reproduction we conclude that in pregnancy any of the 1,25(OH)2D measurements may be appropriate. In lactation, however, either 1,25(OH)2D is not a major factor or 1,25(OH)2D biological activity is inadequately represented by any of the currently available methods.
对35名妊娠晚期和哺乳期女性以及26名对照女性的1,25 - 二羟维生素D(1,25(OH)₂D)生物活性的三个不同指标变化进行了纵向研究。测量了母体血清总1,25(OH)₂D和游离1,25(OH)₂D浓度(通过离心超滤法)以及游离1,25(OH)₂D指数(总1,25(OH)₂D与维生素D结合蛋白(DBP)的摩尔比)。妊娠晚期,与对照组相比,总1,25(OH)₂D浓度显著升高,游离1,25(OH)₂D、DBP浓度以及游离1,25(OH)₂D指数也升高。在哺乳期的前2周,血清总1,25(OH)₂D、游离1,25(OH)₂D和DBP浓度均急剧下降,总1,25(OH)₂D和游离1,25(OH)₂D浓度降至低于对照组的水平。在哺乳期过程中,总1,25(OH)₂D和游离1,25(OH)₂D水平均显著上升,尽管在哺乳期18周时与对照组无差异。相比之下,游离1,25(OH)₂D指数在哺乳期的前2周下降,但维持在该水平,显著低于对照组。尿钙排泄和膳食钙摄入量均与总或游离1,25(OH)₂D、DBP或游离1,25(OH)₂D指数无关。游离1,25(OH)₂D浓度和游离1,25(OH)₂D指数结果的不一致表明,这两种测量生物活性1,25(OH)₂D的方法并不等效。在试图解释人类生殖过程中增加的钙需求时,我们得出结论,在妊娠期间,任何一种1,25(OH)₂D测量方法可能都是合适的。然而,在哺乳期,要么1,25(OH)₂D不是主要因素,要么目前可用的任何方法都不能充分代表1,25(OH)₂D的生物活性。